This article was originally published in The Gray Sheet
Executive SummaryDecides to seek a buyer for Collaborative Diagnostics, its genetic and cancer testing services business. Company President and CEO Robert Hennessey explains in an April 8 release that "the financial commitment required for a successful growth strategy in cancer and genetic diagnostic testing falls well beyond [the] available resources" of the firm. The Waltham, Massachusetts-based genome mapping and DNA sequencing company will "pursue a core strategy to license, discover and develop genetically-based proprietary therapeutics".
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.